Erschienen in:
01.06.2014 | Pancreatic Tumors
Profiling of Autoantibodies in Sera of Pancreatic Cancer Patients
verfasst von:
Yosuke Nagayoshi, MD, Masafumi Nakamura, MD, PhD, Kazuhiro Matsuoka, PhD, Takao Ohtsuka, MD, PhD, Yasuhisa Mori, MD, PhD, Hiroshi Kono, MD, PhD, Teppei Aso, MD, Noboru Ideno, MD, Shunichi Takahata, MD, PhD, Akihide Ryo, MD, PhD, Hiroyuki Takeda, PhD, Tetsuhide Ito, MD, PhD, Yoshinao Oda, MD, PhD, Yaeta Endo, PhD, Tatsuya Sawasaki, PhD, Masao Tanaka, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2014
Einloggen, um Zugang zu erhalten
Abstract
Background
Although autoantibodies to cancer antigens are candidates for biomarkers, no comprehensive studies to detect cancer-specific antibodies have been performed. This study identified autoantibodies in the sera of pancreatic cancer (PC) patients using proteomics based on a wheat germ cell-free protein production system.
Methods
We constructed a biotinylated protein library of 2,183 genes. Interactions between biotinylated proteins and serum antibodies were detected by AlphaScreen® assay. Relative luminescence signals of each protein in 37 PC patients and 20 healthy controls were measured, and their sensitivity and specificity for PC were calculated.
Results
Luminescence signals of nine proteins were significantly higher than those of healthy controls, with calcium and integrin binding 1 (CIB1) protein showing the greatest significance (p = 0.002). Sensitivity, specificity, positive predictive value and negative predictive value of CIB1 autoantibody alone for PC were 76, 70, 82, and 61 %, respectively, and 97, 35, 74, and 88 %, respectively, when the four most significant proteins were combined. Presence of these autoantibodies did not vary significantly with other clinicopathological characteristics.
Conclusion
Several autoantibodies, including CIB1, are potential biomarkers for PC.